FDA Approves Drug Combination for TreatingMesothelioma “Today's approval of nivolumab plusipilimumab providesanew treatment that has demonstrated an improvement in overallsurvival for patients with malignant pleural mesothelioma,”said Richard Pazdur...
OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate ...
In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United Stat...
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update 2021, ESMO Open Citation Excerpt : Ipilimumab induces de novo antitumor T-cell responses, including an increase in memory...
Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “These new findings from CheckMate -9ER and the recent FDA approval of the combination regimen are extremely encouraging as we further explore the potential ofCABOMETYXin combination with immunotherapies to help...